BioInvent International AB (publ)

BATS-CHIXE:BINVS Stock Report

Market Cap: SEK 2.1b

BioInvent International Valuation

Is BINVS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BINVS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BINVS (SEK34.75) is trading below our estimate of fair value (SEK100.41)

Significantly Below Fair Value: BINVS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BINVS?

Key metric: As BINVS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BINVS. This is calculated by dividing BINVS's market cap by their current revenue.
What is BINVS's PS Ratio?
PS Ratio6.7x
SalesSEK 310.39m
Market CapSEK 2.07b

Price to Sales Ratio vs Peers

How does BINVS's PS Ratio compare to its peers?

The above table shows the PS ratio for BINVS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.4x
AVCT Avacta Group
7.9x0.4%UK£179.3m
BVXP Bioventix
14.4xn/aUK£195.7m
TRX Tissue Regenix Group
1.6x15.1%UK£40.6m
AREC Arecor Therapeutics
5.8x35.2%UK£28.3m
BINVS BioInvent International
6.7x50.7%SEK 2.1b

Price-To-Sales vs Peers: BINVS is good value based on its Price-To-Sales Ratio (6.7x) compared to the peer average (24.3x).

Price to Sales Ratio vs Industry

How does BINVS's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.41b
OXB Oxford Biomedica
4.5x21.0%US$554.49m
TRX Tissue Regenix Group
1.6x15.1%US$50.88m
PBX ProBiotix Health
4.8xn/aUS$12.88m
No. of Companies7PS020406080100+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BINVS is good value based on its Price-To-Sales Ratio (6.7x) compared to the UK Biotechs industry average (17.2x).

Price to Sales Ratio vs Fair Ratio

What is BINVS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BINVS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BINVS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

4.0%

1Y

-23.5%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

7D

-1.7%

1Y

-6.3%